Want to see MLSS full AI Analyst Report?
MLSS Stock Chart & Stats
$0.54
$0.01(3.13%)
At close: 4:00 PM EDT
$0.54
$0.01(3.13%)
Day’s Range― - ―
52-Week Range$0.22 - $0.58
Previous Close$0.4
Volume145.61K
Average Volume (3M)87.25K
Market Cap
$30.18M
Enterprise Value$28.44M
Total Cash (Recent Filing)$2.07M
Total Debt (Recent Filing)$615.70K
Price to Earnings (P/E)―
Beta0.90
Next Earnings
Nov 12, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding90,644,400
10 Day Avg. Volume92,103
30 Day Avg. Volume87,251
Financial Highlights & Ratios
PEG Ratio-0.21
Price to Book (P/B)7.97
Price to Sales (P/S)2.50
P/FCF Ratio-7.64
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue3.02
Enterprise Value/Gross Profit4.34
Enterprise Value/Ebitda-7.26
Forecast
1Y Price Target
$1.50Price Target Upside177.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.04
Revenue Forecast (FY)$9.97M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And GuidanceRecent revenue growth and reaffirmed full-year guidance indicate improving commercial execution and greater visibility into the company’s expansion path. Continued growth would help Milestone Scientific leverage its operating platform, support investment in sales channels, and move the business closer to sustainable scale.
Medicare Reimbursement ExpansionBroader Medicare reimbursement can reduce adoption friction for CompuFlo by improving provider economics and supporting direct regional sales. Coverage across multiple jurisdictions gives the company a structural route to expand utilization, strengthen commercialization, and convert clinical interest into recurring revenue.
Clinical Product ValidationIndependent clinical evidence showing materially lower complication odds strengthens CompuFlo’s value proposition with physicians, health systems, and payers. Such validation can support adoption and reimbursement discussions over time, creating a durable commercial advantage beyond short-term promotional activity.
Bears Say
Persistent Losses And Cash BurnThe company remains dependent on continued revenue growth, cost reductions, or external financing because operations are not yet self-funding. Persistent losses and negative free cash flow limit financial flexibility, reduce capacity for internal investment, and increase execution risk until profitability and cash generation improve.
Margin And Product Cost PressureGross-margin compression shows that higher sales are not translating fully into incremental gross profit. If tariffs, import-related expenses, and unfavorable mix persist, they could constrain operating leverage and delay the path to breakeven, making durable profitability more dependent on pricing and cost control.
Dilution And Capital SensitivityExpanded share authorization and a much larger equity incentive plan give Milestone Scientific financing and compensation flexibility, but also increase potential dilution. Combined with convertible debt and negative cash generation, this may limit existing shareholders’ participation in future value creation if additional capital is required.
Milestone Scientific News
MLSS FAQ
What was Milestone Scientific’s price range in the past 12 months?
Milestone Scientific lowest stock price was $0.22 and its highest was $0.58 in the past 12 months.
What is Milestone Scientific’s market cap?
Milestone Scientific’s market cap is $30.18M.
When is Milestone Scientific’s upcoming earnings report date?
Milestone Scientific’s upcoming earnings report date is Nov 12, 2026 which is in 22 days.
How were Milestone Scientific’s earnings last quarter?
Milestone Scientific released its earnings results on Aug 14, 2026. The company reported -$0.01 earnings per share for the quarter.
Is Milestone Scientific overvalued?
According to Wall Street analysts Milestone Scientific’s price is currently Undervalued.
Does Milestone Scientific pay dividends?
Milestone Scientific does not currently pay dividends.
What is Milestone Scientific’s EPS estimate?
Milestone Scientific’s EPS estimate is -0.01.
How many shares outstanding does Milestone Scientific have?
Milestone Scientific has 90,644,400 shares outstanding.
What happened to Milestone Scientific’s price movement after its last earnings report?
Milestone Scientific reported an EPS of -$0.01 in its last earnings report. Following the earnings report the stock price went down -10.488%.
Which hedge fund is a major shareholder of Milestone Scientific?
Currently, no hedge funds are holding shares in MLSS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Milestone Scientific Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$1.50 (177.78% Upside)
$1.50 (177.78% Upside)
Blogger Sentiment
Bullish
MLSS Sentiment 100%
Sector Average 67%
Sector Average 67%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-22.11%
12-Months-Change
Fundamentals
Return on Equity
-149.08%
Trailing 12-Months
Asset Growth
3.69%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Milestone Scientific
Milestone Scientific Inc. is dedicated to the innovation, refinement, and global distribution of advanced diagnostic and therapeutic injection technologies and devices. These solutions cater to the medical, dental, and cosmetic industries, with a presence in the United States, China, and other international markets. The company's operations are divided into two main segments: Dental and Medical. Within its Dental division, key products include CompuDent and the STA Single Tooth Anesthesia System, both instrumental for delivering local anesthetics across all dental procedures. For broader applications, the firm offers CompuFlo, a sophisticated computer-controlled system capable of delivering drugs, anesthetics, and other medicaments comfortably and precisely, as well as aspirating bodily fluids or prior injections. Complementing this, a disposable injection handpiece provides precise tactile control during administration. In the Medical segment, Milestone Scientific introduces the CompuFlo Epidural, a computer-guided anesthesia system designed for a variety of medical applications. Additionally, their CompuMed system is utilized in numerous specialized procedures, including plastic surgery, hair restoration, colorectal surgery, podiatry, dermatology, and orthopedics, among others. Headquartered in Livingston, New Jersey, Milestone Scientific Inc. was established in 1989.
MLSS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple clear operational and commercial wins — robust revenue growth, a large percentage increase in medical segment revenue, important Medicare reimbursement milestones, strong third-party clinical validation (91% reduction in complication odds), new federal distribution access, and improved expense discipline that reduced net loss. Offsetting these positives are margin pressure from increased product/import costs, a non-recurring ~ $500K international order that tempers near-term sequential revenue (Q3 guide below Q2), medical revenue still coming from a small base, staffing capacity constraints for lead and reimbursement follow-up, and a modest cash balance that could require monitoring. On balance the call emphasized measurable commercial progress and validation and management provided a path to scale reimbursement and federal channels, while acknowledging operational headwinds to be managed.View all MLSS earnings summariesMLSS Stock 12 Month Forecast
Average Price Target
$1.50
▲(177.78% Upside)
Technical Analysis
Retractable Technologies
―
Precision Optics Corporation
―
Nephros
―
Femasys
―
NexGel Inc
―
Ownership Overview
9.82% Insiders
2.86% Mutual Funds
0.39% Other Institutional Investors
84.44% Public Companies and
Individual Investors